Prostate cancer: The main risk and protective factors-Epigenetic modifications

Annales d'Endocrinologie

Volumn 76, Issue 1, 2015, Pages 25-41

  Adjakly, Mawussi ^a,b   Ngollo, Marjolaine ^a,b   Dagdemir, Aslihan ^a,b   Judes, Gaëlle ^a,b   Pajon, Amaury ^a,b   Karsli Ceppioglu, Seher ^a,b,c   Penault Llorca, Frédérique ^a,b   Boiteux, Jean Paul ^d   Bignon, Yves Jean ^a,b   Guy, Laurent ^b,d   Bernard Gallon, Dominique ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Hospital Universitario de Marmara   (Turkey)

^d SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Diet; Epigenetics; Phytoestrogens; Prostate cancer; Risk factors

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ALPHA TOCOPHEROL; CALCIUM; CHLORDECONE; COUMESTAN; DAIDZEIN; DNA; ESTRADIOL; FAT; GENISTEIN; ISOFLAVONOID; LIGNAN DERIVATIVE; LYCOPENE; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PESTICIDE; PHYTOESTROGEN; POMEGRANATE EXTRACT; SELENIUM; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; VEGETABLE OIL; VITAMIN D; ZINC; ANTIOXIDANT; ISOFLAVONE DERIVATIVE;

AGE; ANTIOXIDANT ACTIVITY; APOPTOSIS; BINDING AFFINITY; BIOAVAILABILITY; BRCA2 GENE; BROCCOLI; CABBAGE; CAGE GENE; CALCIUM INTAKE; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CAPB GENE; CARCINOGENESIS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); CRIP1 GENE; CYP1B1 GENE; DAIRY PRODUCT; DIET; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; EPIGENETICS; ETHNIC DIFFERENCE; ETHNICITY; EXPERIMENTAL STUDY; FRUIT; GARLIC; GENE; GENETIC PREDISPOSITION; GENETICS; HISTONE MODIFICATION; HPC1 GENE; HPSE GENE; HUMAN; LIFESTYLE; LINE 1 GENE; METABOLISM; NONHUMAN; OCCUPATIONAL EXPOSURE; ONION; PCAP GENE; PROSTATE CANCER; RECEPTOR BINDING; REVIEW; S100P GENE; SMOKING; SOYBEAN; TEA; TRANSCRIPTION REGULATION; UPA GENE; VEGETABLE; WNT5A GENE; XPC GENE; ADULT; GENETIC EPIGENESIS; HISTONE CODE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTOR;

ADULT; ANTIOXIDANTS; DIET; DNA METHYLATION; EPIGENESIS, GENETIC; GENISTEIN; HISTONE CODE; HUMANS; ISOFLAVONES; MALE; MICRORNAS; MIDDLE AGED; PHYTOESTROGENS; PROSTATIC NEOPLASMS; RISK FACTORS; SOYBEANS;

EID: 84924059330     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2014.09.001     Document Type: Article

References (164)

1. Belot A., Grosclaude P., Bossard N., Jougla E., Benhamou E., Delafosse P., et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique 2008, 56(3):159-175.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
3. Center M.M., Jemal A., Lortet-Tieulent J., Ward E., Ferlay J., Brawley O., et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012, 61(6):1079-1092.
4. Brawley O.W. Prostate cancer epidemiology in the United States. World J Urol 2012, 30(2):195-200.
5. Fromont G., Yacoub M., Valeri A., Mangin P., Vallancien G., Cancel-Tassin G., et al. Differential expression of genes related to androgen and estrogen metabolism in hereditary versus sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(6):1505-1509.
6. Xu J. Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet 2000, 66(3):945-957.
7. Berthon P., Valeri A., Cohen-Akenine A., Drelon E., Paiss T., Wohr G., et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998, 62(6):1416-1424.
8. Cancel-Tassin G., Latil A., Valeri A., Mangin P., Fournier G., Berthon P., et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001, 9(2):135-142.
9. Cussenot O., Cancel-Tassin G. [Genetic susceptibility to prostate cancer]. Med Sci (Paris) 2004, 20(5):562-568.
10. Fournier G., Valeri A., Mangin P., Cussenot O. [Prostate cancer epidemiology. Risk factors. Pathology]. Ann Urol (Paris) 2004, 38(5):187-206.
11. Valeri A., Fournier G., Morin V., Morin J.F., Drelon E., Mangin P., et al. Early-onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first-degree relatives. Int J Cancer 2000, 86(6):883-887.
12. Edwards S.M., Kote-Jarai Z., Meitz J., Hamoudi R., Hope Q., Osin P., et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003, 72(1):1-12.
13. Kheirandish P., Chinegwundoh F. Ethnic differences in prostate cancer. Br J Cancer 2011, 105(4):481-485.
14. Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995, 55(9):1937-1940.
15. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 1999, 8(10):901-905.
16. Prins G.S., Korach K.S. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 2008, 73(3):233-244.
17. Prins G.S., Tang W.Y., Belmonte J., Ho S.M. Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis. Basic Clin Pharmacol Toxicol 2008, 102(2):134-138.
18. Fenichel P., Chevalier N., Brucker-Davis F. Bisphenol A: an endocrine and metabolic disruptor. Ann Endocrinol (Paris) 2013, 74(3):211-220.
19. Multigner L., Ndong J.R., Giusti A., Romana M., Delacroix-Maillard H., Cordier S., et al. Chlordecone exposure and risk of prostate cancer. J Clin Oncol 2010, 28(21):3457-3462.
20. Band P.R., Abanto Z., Bert J., Lang B., Fang R., Gallagher R.P., et al. Prostate cancer risk and exposure to pesticides in British Columbia farmers. Prostate 2011, 71(2):168-183.
21. Ragin C., Davis-Reyes B., Tadesse H., Daniels D., Bunker C.H., Jackson M., et al. Farming, reported pesticide use, and prostate cancer. Am J Mens Health 2013, 7(2):102-109.
22. Koutros S., Beane Freeman L.E., Lubin J.H., Heltshe S.L., Andreotti G., Barry K.H., et al. Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study. Am J Epidemiol 2013, 177(1):59-74.
23. Barry K.H., Koutros S., Andreotti G., Sandler D.P., Burdette L.A., Yeager M., et al. Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk. Carcinogenesis 2012, 33(2):331-337.
24. Koutros S., Berndt S.I., Hughes Barry K., Andreotti G., Hoppin J.A., Sandler D.P., et al. Genetic susceptibility loci, pesticide exposure and prostate cancer risk. PLoS One 2013, 8(4):e58195.
25. Andreotti G., Koutros S., Berndt S.I., Hughes Barry K., Hou L., Hoppin J.A., et al. The interaction between pesticide use and genetic variants involved in lipid metabolism on prostate cancer risk. J Cancer Epidemiol 2012, 2012:358076.
26. Muir C.S., Nectoux J., Staszewski J. The epidemiology of prostatic cancer. Geographical distribution and time-trends. Acta Oncol 1991, 30(2):133-140.
27. Chung W.K., Leibel RL: The links between obesity, leptin, and prostate cancer. Cancer J 2006, 12(3):178-181.
28. Fair W.R., Fleshner N.E., Heston W. Cancer of the prostate: a nutritional disease?. Urology 1997, 50(6):840-848.
29. Strom S.S., Yamamura Y., Forman M.R., Pettaway C.A., Barrera S.L., DiGiovanni J. Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer 2008, 122(11):2581-2585.
30. Desgrandchamps F., Bastien L. [Nutrition, dietary supplements and prostate cancer]. Prog Urol 2010, 20(8):560-565.
31. Kesse E., Bertrais S., Astorg P., Jaouen A., Arnault N., Galan P., et al. Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplementation en Vitamines et Mineraux Antioxydants) study. Br J Nutr 2006, 95(3):539-545.
32. Tseng M., Breslow R.A., Graubard B.I., Ziegler R.G. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 2005, 81(5):1147-1154.
33. Butler L.M., Wong A.S., Koh W.P., Wang R., Yuan J.M., Yu M.C. Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res 2010, 70(12):4941-4948.
34. Raimondi S., Mabrouk J.B., Shatenstein B., Maisonneuve P., Ghadirian P. Diet and prostate cancer risk with specific focus on dairy products and dietary calcium: a case-control study. Prostate 2010, 70(10):1054-1065.
35. Stacewicz-Sapuntzakis M., Borthakur G., Burns J.L., Bowen P.E. Correlations of dietary patterns with prostate health. Mol Nutr Food Res 2008, 52(1):114-130.
36. Heinonen O.P., Albanes D., Virtamo J., Taylor P.R., Huttunen J.K., Hartman A.M., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90(6):440-446.
37. Clark L.C., Combs G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276(24):1957-1963.
38. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301(1):39-51.
39. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306(14):1549-1556.
40. Malik A., Afaq F., Sarfaraz S., Adhami V.M., Syed D.N., Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005, 102(41):14813-14818.
41. Galeone C., Pelucchi C., Levi F., Negri E., Franceschi S., Talamini R., et al. Onion and garlic use and human cancer. Am J Clin Nutr 2006, 84(5):1027-1032.
42. Kolonel L.N., Hankin J.H., Whittemore A.S., Wu A.H., Gallagher R.P., Wilkens L.R., et al. Vegetables, fruits, legumes and prostate cancer: a multi-ethnic case-control study. Cancer Epidemiol Biomarkers Prev 2000, 9(8):795-804.
43. Singh R.P., Tyagi A.K., Dhanalakshmi S., Agarwal R., Agarwal C. Grape seed extract inhibits advanced human prostate tumour growth and angiogenesis and upregulates insulin-like growth factor binding protein-3. Int J Cancer 2004, 108(5):733-740.
44. McCann S.E., Ambrosone C.B., Moysich K.B., Brasure J., Marshall J.R., Freudenheim J.L., et al. Intakes of selected nutrients, foods, and phytochemicals and prostate cancer risk in western New York. Nutr Cancer 2005, 53(1):33-41.
45. Wu K., Erdman J.W., Schwartz S.J., Platz E.A., Leitzmann M., Clinton S.K., et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2004, 13(2):260-269.
46. Jian L., Du C.J., Lee A.H., Binns C.W. Do dietary lycopene and other carotenoids protect against prostate cancer?. Int J Cancer 2005, 113(6):1010-1014.
47. Schuurman A.G., Goldbohm R.A., Brants H.A., van den Brandt P.A. A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). Cancer Causes Control 2002, 13(6):573-582.
48. Khan N., Adhami V.M., Mukhtar H. Review: green tea polyphenols in chemoprevention of prostate cancer: preclinical and clinical studies. Nutr Cancer 2009, 61(6):836-841.
49. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 2012, 41(1):353-361.
50. Kraus G.A., Zhang N. Hydrogen-atom Abstraction/Cyclization in synthesis. Direct syntheses of coumestan and coumestrol. J Org Chem 2000, 65(18):5644-5646.
51. Heinonen S., Nurmi T., Liukkonen K., Poutanen K., Wahala K., Deyama T., et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001, 49(7):3178-3186.
52. Wenzel E., Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005, 49(5):472-481.
53. Manach C., Scalbert A., Morand C., Remesy C., Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004, 79(5):727-747.
54. Williams C.A., Grayer R.J. Anthocyanins and other flavonoids. Nat Prod Rep 2004, 21(4):539-573.
55. Heim K.E., Tagliaferro A.R., Bobilya D.J. Flavonoid anti-oxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem 2002, 13(10):572-584.
56. Trock B.J., Hilakivi-Clarke L., Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst 2006, 98(7):459-471.
57. Setchell K.D., Brown N.M., Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002, 132(12):3577-3584.
58. Keinan-Boker L., van Der Schouw Y.T., Grobbee D.E., Peeters P.H. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 2004, 79(2):282-288.
59. Setchell K.D., Brown N.M., Desai P., Zimmer-Nechemias L., Wolfe B.E., Brashear W.T., et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001, 131(4 Suppl):1362S-1375S.
60. Atkinson C., Frankenfeld C.L., Lampe J.W. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005, 230(3):155-170.
61. Bolca S., Possemiers S., Herregat A., Huybrechts I., Heyerick A., De Vriese S., et al. Microbial and dietary factors are associated with the equol producer phenotype in healthy post-menopausal women. J Nutr 2007, 137(10):2242-2246.
62. Shelnutt S.R., Cimino C.O., Wiggins P.A., Ronis M.J., Badger T.M. Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage. Am J Clin Nutr 2002, 76(3):588-594.
63. Guy L., Vedrine N., Urpi-Sarda M., Gil-Izquierdo A., Al-Maharik N., Boiteux J.P., et al. Orally administered isoflavones are present as glucuronides in the human prostate. Nutr Cancer 2008, 60(4):461-468.
64. Barnes S. Soy isoflavones-phytoestrogens and what else?. J Nutr 2004, 134(5):1225S-1228S.
65. Munetsuna E., Hojo Y., Hattori M., Ishii H., Kawato S., Ishida A., et al. Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology 2009, 150(9):4260-4269.
66. Winters S.J., Moore J.P. Intra-pituitary regulation of gonadotrophs in male rodents and primates. Reproduction 2004, 128(1):13-23.
67. Jensen E.V., Jacobson H.I., Walf A.A., Frye C.A. Estrogen action: a historic perspective on the implications of considering alternative approaches. Physiol Behav 2010, 99(2):151-162.
68. Miller C.P., Collini M.D., Harris H.A. Constrained phytoestrogens and analogues as ERbeta-selective ligands. Bioorg Med Chem Lett 2003, 13(14):2399-2403.
69. Mueller S.O. Overview of in vitro tools to assess the estrogenic and anti-estrogenic activity of phytoestrogens. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 777(1-2):155-165.
70. Nikov G.N., Hopkins N.E., Boue S., Alworth W.L. Interactions of dietary estrogens with human estrogen receptors and the effect on estrogen receptor-estrogen response element complex formation. Environ Health Perspect 2000, 108(9):867-872.
71. An J., Tzagarakis-Foster C., Scharschmidt T.C., Lomri N., Leitman D.C. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001, 276(21):17808-17814.
72. Beck V., Unterrieder E., Krenn L., Kubelka W., Jungbauer A. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2003, 84(2-3):259-268.
73. Kim S., Shin H.J., Kim S.Y., Kim J.H., Lee Y.S., Kim D.H., et al. Genistein enhances expression of genes involved in fatty acid catabolism through activation of PPARalpha. Mol Cell Endocrinol 2004, 220(1-2):51-58.
74. Dang Z.C., Audinot V., Papapoulos S.E., Boutin J.A., Lowik C.W. Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 2003, 278(2):962-967.
75. Wang X., Clubbs E.A., Bomser J.A. Genistein modulates prostate epithelial cell proliferation via estrogen- and extracellular signal-regulated kinase-dependent pathways. J Nutr Biochem 2006, 17(3):204-210.
76. Bhatia N., Agarwal R. Detrimental effect of cancer-preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate 2001, 46(2):98-107.
77. Ho S.M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem 2004, 91(3):491-503.
78. Severson R.K., Nomura A.M., Grove J.S., Stemmermann G.N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res 1989, 49(7):1857-1860.
79. Lee M.M., Wang R.T., Hsing A.W., Gu F.L., Wang T., Spitz M. Case-control study of diet and prostate cancer in China. Cancer Causes Control 1998, 9(6):545-552.
80. Jacobsen B.K., Knutsen S.F., Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 1998, 9(6):553-557.
81. Kurahashi N., Iwasaki M., Inoue M., Sasazuki S., Tsugane S. Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. J Clin Oncol 2008, 26(36):5923-5929.
82. Heald C.L., Ritchie M.R., Bolton-Smith C., Morton M.S., Alexander F.E. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr 2007, 98(2):388-396.
83. Adlercreutz H., Markkanen H., Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993, 342(8881):1209-1210.
84. Marks L.S., Kojima M., Demarzo A., Heber D., Bostwick D.G., Qian J., et al. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology 2004, 64(4):765-771.
85. Adjakly M., Ngollo M., Boiteux J.P., Bignon Y.J., Guy L., Bernard-Gallon D. Genistein and daidzein: different molecular effects on prostate cancer. Anticancer Res 2013, 33(1):39-44.
86. Basak S., Pookot D., Noonan E.J., Dahiya R. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther 2008, 7(10):3195-3202.
87. Swami S., Krishnan A.V., Moreno J., Bhattacharyya R.S., Gardner C., Brooks J.D., et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int J Cancer 2009, 124(9):2050-2059.
88. Rabiau N., Kossai M., Braud M., Chalabi N., Satih S., Bignon Y.J., et al. Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol 2010, 34(2):200-206.
89. Day J.K., Bauer A.M., DesBordes C., Zhuang Y., Kim B.E., Newton L.G., et al. Genistein alters methylation patterns in mice. J Nutr 2002, 132(8 Suppl.):2419S-2423S.
90. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res 2005, 11(19 Pt 1):7033-7041.
91. Chang B.L., Isaacs S.D., Wiley K.E., Gillanders E.M., Zheng S.L., Meyers D.A., et al. Genome-wide screen for prostate cancer-susceptibility genes in men with clinically significant disease. Prostate 2005, 64(4):356-361.
92. Majid S., Dar A.A., Saini S., Chen Y., Shahryari V., Liu J., et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res 2010, 70(7):2809-2818.
93. Rabiau N., Trraf H.K., Adjakly M., Bosviel R., Guy L., Fontana L., et al. miRNAs differentially expressed in prostate cancer cell lines after soy treatment. In Vivo 2011, 25(6):917-921.
94. Hoda M.R., Mohammed N., Theil G., Fischer K., Fornara P. [Obesity and prostate cancer. Role of adipocytokines and clinical implications]. Urologe A 2012, 51(9):1253-1260.
95. Liu Y., Chen Z., Wei Q., Yuan F., Zhi Y., Song B., et al. Poly (AT) polymorphism in the XPC gene and smoking enhance the risk of prostate cancer in a low-risk Chinese population. Cancer Genet 2012, 205(5):205-211.
96. Warnecke P.M., Bestor T.H. Cytosine methylation and human cancer. Curr Opin Oncol 2000, 12(1):68-73.
97. Knudson A.G. Karnofsky Memorial Lecture. Hereditary cancer: theme and variations. J Clin Oncol 1997, 15(10):3280-3287.
98. Baylin S., Bestor T.H. Altered methylation patterns in cancer cell genomes: cause or consequence?. Cancer Cell 2002, 1(4):299-305.
99. Jeronimo C., Bastian P.J., Bjartell A., Carbone G.M., Catto J.W., Clark S.J., et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011, 60(4):753-766.
100. Dunn B.K. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003, 983:28-42.
101. Florl A.R., Steinhoff C., Muller M., Seifert H.H., Hader C., Engers R., et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004, 91(5):985-994.
102. Pakneshan P., Szyf M., Rabbani S.A. Hypomethylation of urokinase (uPA) promoter in breast and prostate cancer: prognostic and therapeutic implications. Curr Cancer Drug Targets 2005, 5(7):471-488.
103. Ogishima T., Shiina H., Breault J.E., Tabatabai L., Bassett W.W., Enokida H., et al. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer. Clin Cancer Res 2005, 11(3):1028-1036.
104. Tokizane T., Shiina H., Igawa M., Enokida H., Urakami S., Kawakami T., et al. Cytochrome P450 1B1 is overexpressed and regulated by hypomethylation in prostate cancer. Clin Cancer Res 2005, 11(16):5793-5801.
105. Cho B., Lee H., Jeong S., Bang Y.J., Lee H.J., Hwang K.S., et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in pre-malignant stage of gastric carcinoma. Biochem Biophys Res Commun 2003, 307(1):52-63.
106. Wang Q., Williamson M., Bott S., Brookman-Amissah N., Freeman A., Nariculam J., et al. Hypomethylation of WNT5A, CRIP1 and S100P in prostate cancer. Oncogene 2007, 26(45):6560-6565.
107. Sunami E., de Maat M., Vu A., Turner R.R., Hoon D.S. LINE-1 hypomethylation during primary colon cancer progression. PLoS One 2011, 6(4):e18884.
108. Neuhausen A., Florl A.R., Grimm M.O., Schulz W.A. DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther 2006, 5(8):993-1001.
109. West R.L., Lee J.M., Maroun L.E. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 1995, 6(2):141-146.
110. Cai M., Tian J., Zhao G.H., Luo W., Zhang B.R. Study of methylation levels of parkin gene promoter in Parkinson's disease patients. Int J Neurosci 2011, 121(9):497-502.
111. Obermann-Borst S.A., van Driel L.M., Helbing W.A., de Jonge R., Wildhagen M.F., Steegers E.A., et al. Congenital heart defects and biomarkers of methylation in children: a case-control study. Eur J Clin Invest 2011, 41(2):143-150.
112. Park J.Y. Promoter hypermethylation in prostate cancer. Cancer Control 2010, 17(4):245-255.
113. Mishra D.K., Chen Z., Wu Y., Sarkissyan M., Koeffler H.P., Vadgama J.V. Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 2010, 9(1):33-45.
114. Vanaja D.K., Ehrich M., Van den Boom D., Cheville J.C., Karnes R.J., Tindall D.J., et al. Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest 2009, 27(5):549-560.
115. Richiardi L., Fiano V., Vizzini L., De Marco L., Delsedime L., Akre O., et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009, 27(19):3161-3168.
116. Alumkal J.J., Zhang Z., Humphreys E.B., Bennett C., Mangold L.A., Carducci M.A., et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008, 72(6):1234-1239.
117. Rabiau N., Thiam M.O., Satih S., Guy L., Kemeny J.L., Boiteux J.P., et al. Methylation analysis of BRCA1, RASSF1, GSTP1 and EPHB2 promoters in prostate biopsies according to different degrees of malignancy. In Vivo 2009, 23(3):387-391.
118. Majumdar S., Buckles E., Estrada J., Koochekpour S. Aberrant DNA methylation and prostate cancer. Curr Genomics 2011, 12(7):486-505.
119. Vardi A., Bosviel R., Rabiau N., Adjakly M., Satih S., Dechelotte P., et al. Soy phytoestrogens modify DNA methylation of GSTP1, RASSF1A, EPH2 and BRCA1 promoter in prostate cancer cells. In Vivo 2010, 24(4):393-400.
120. Bosviel R., Michard E., Lavediaux G., Kwiatkowski F., Bignon Y.J., Bernard-Gallon DJ: Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. Clin Chim Acta 2011, 412(15-16):1472-1475.
121. Mahapatra S., Klee E.W., Young C.Y., Sun Z., Jimenez R.E., Klee G.G., et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012, 18(10):2882-2895.
122. Colombel M., Ricci E., Picard A., Bourrelly E. [Hypermethylation and prostate cancer]. Prog Urol 2010, 20(6):408-415.
123. Nakayama M., Gonzalgo M.L., Yegnasubramanian S., Lin X., De Marzo A.M., Nelson W.G. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004, 91(3):540-552.
124. Jeronimo C., Henrique R., Hoque M.O., Ribeiro F.R., Oliveira J., Fonseca D., et al. Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker. Clin Cancer Res 2004, 10(12 Pt 1):4010-4014.
125. Adjakly M., Bosviel R., Rabiau N., Boiteux J.P., Bignon Y.J., Guy L., et al. DNA methylation and soy phytoestrogens: quantitative study in DU-145 and PC-3 human prostate cancer cell lines. Epigenomics 2011, 3(6):795-803.
126. Hesson L.B., Packham D., Pontzer E., Funchain P., Eng C., Ward R.L. A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. Biol Proced Online 2012, 14(1):5.
127. Hill V.K., Hesson L.B., Dansranjavin T., Dallol A., Bieche I., Vacher S., et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010, 9:51.
128. Taby R., Issa J.P. Cancer epipenetics. CA Cancer J Clin 2010, 60(6):376-392.
129. Shenouda S.K., Alahari S.K. MicroRNA function in cancer: oncogene or a tumour suppressor?. Cancer Metastasis Rev 2009, 28(3-4):369-378.
130. Babashah S., Soleimani M: The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. Eur J Cancer 2011, 47(8):1127-1137.
131. Ambs S., Prueitt R.L., Yi M., Hudson R.S., Howe T.M., Petrocca F., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008, 68(15):6162-6170.
132. Sun R., Fu X., Li Y., Xie Y., Mao Y. Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics 2009, 10:93.
133. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006, 103(7):2257-2261.
134. Friedman J.M., Jones P.A., Liang G. The tumour suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb-group protein EZH2 in cancer. Cell Cycle 2009, 8(15):2313-2314.
135. Rouhi A., Mager D.L., Humphries R.K., Kuchenbauer F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008, 19(7-8):517-525.
136. Vrba L., Jensen T.J., Garbe J.C., Heimark R.L., Cress A.E., Dickinson S., et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One 2010, 5(1):e8697.
137. Pang Y., Young C.Y., Yuan H: MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 2010, 42(6):363-369.
138. Stirzaker C., Song J.Z., Davidson B., Clark S.J. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 2004, 64(11):3871-3877.
139. Nakayama T., Watanabe M., Yamanaka M., Hirokawa Y., Suzuki H., Ito H., et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest 2001, 81(7):1049-1057.
140. Kawamoto K., Okino S.T., Place R.F., Urakami S., Hirata H., Kikuno N., et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 2007, 13(9):2541-2548.
141. Ke X.S., Qu Y., Rostad K., Li W.C., Lin B., Halvorsen O.J., et al. Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One 2009, 4(3):e 4687.
142. Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., et al. Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 2009, 174(5):1619-1628.
143. Lu T.Y., Kao C.F., Lin C.T., Huang D.Y., Chiu C.Y., Huang Y.S., et al. DNA methylation and histone modification regulate silencing of OPG during tumour progression. J Cell Biochem 2009, 108(1):315-325.
144. Bock C.H., Peyser P.A., Gruber S.B., Bonnell S.E., Tedesco K.L., Cooney K.A. Prostate cancer early detection practices among men with a family history of disease. Urology 2003, 62(3):470-475.
145. Kommu S., Edwards S., Eeles R. The clinical genetics of prostate cancer. Hered Cancer Clin Pract 2004, 2(3):111-121.
146. Edwards S.M., Eeles R.A. Unravelling the genetics of prostate cancer. Am J Med Genet C Semin Med Genet 2004, 129C(1):65-73.
147. Crawford E.D. Epidemiology of prostate cancer. Urology 2003, 62(6 Suppl. 1):3-12.
148. Alberti C: Hereditary/familial versus sporadic prostate cancer: few indisputable genetic differences and many similar clinicopathological features. Eur Rev Med Pharmacol Sci 2010, 14(1):31-41.
149. Sundararajan S., Ahmed A., Goodman O.B. The relevance of BRCA genetics to prostate cancer pathogenesis and treatment. Clin Adv Hematol Oncol 2011, 9(10):748-755.
150. Reddy S., Shapiro M., Morton R., Brawley O.W. Prostate cancer in black and white Americans. Cancer Metastasis Rev 2003, 22(1):83-86.
151. Akhtar F.Z., Garabrant D.H., Ketchum N.S., Michalek J.E. Cancer in US Air Force veterans of the Vietnam War. J Occup Environ Med 2004, 46(2):123-136.
152. Chamie K., DeVere White R.W., Lee D., Ok J.H., Ellison L.M. Agent Orange exposure. Vietnam War veterans, and the risk of prostate cancer. Cancer 2008, 113(9):2464-2470.
153. Van Maele-Fabry G., Willems J.L. Prostate cancer among pesticide applicators: a meta-analysis. Int Arch Occup Environ Health 2004, 77(8):559-570.
154. Van Maele-Fabry G., Willems J.L. Occupation related pesticide exposure and cancer of the prostate: a meta-analysis. Occup Environ Med 2003, 60(9):634-642.
155. Mullins J.K., Loeb S. Environmental exposures and prostate cancer. Urol Oncol 2012, 30(2):216-219.
156. Mink P.J., Adami H.O., Trichopoulos D., Britton N.L., Mandel J.S. Pesticides and prostate cancer: a review of epidemiologic studies with specific agricultural exposure information. Eur J Cancer Prev 2008, 17(2):97-110.
157. Huncharek M., Haddock K.S., Reid R., Kupelnick B. Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health 2010, 100(4):693-701.
158. Plaskon L.A., Penson D.F., Vaughan T.L., Stanford J.L. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomarkers Prev 2003, 12(7):604-609.
159. Straif K., Weiland S.K., Bungers M., Holthenrich D., Taeger D., Yi S., et al. Exposure to high concentrations of nitrosamines and cancer mortality among a cohort of rubber workers. Occup Environ Med 2000, 57(3):180-187.
160. Yan L., Spitznagel E.L. Meta-analysis of soy food and risk of prostate cancer in men. Int J Cancer 2005, 117(4):667-669.
161. Yan L., Spitznagel E.L. Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. Am J Clin Nutr 2009, 89(4):1155-1163.
162. Kurahashi N., Iwasaki M., Sasazuki S., Otani T., Inoue M., Tsugane S. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 2007, 16(3):538-545.
163. Hwang Y.W., Kim S.Y., Jee S.H., Kim Y.N., Nam C.M. Soy food consumption and risk of prostate cancer: a meta-analysis of observational studies. Nutr Cancer 2009, 61(5):598-606.
164. Agence française de sécurité sanitaire des aliments Sécurité et bénéfices des phyto-œstrogènes apportés par l'alimentation. Recommandations 2005, 1-440.